Every material Form 8-K Wave Life Sciences, Inc. has filed with the SEC since May 18, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Wave Life Sciences reported third quarter 2026 results, with revenue recognized of $13.2 million, up from $7.6 million a year earlier. Net loss widened to $61.9 million from $53.9 million, though the loss per share improved to $0.30 from $0.32 as the weighted-average share count rose. The company said cash, cash equivalents, and marketable securities were $431.0 million at September 30, 2026, with a cash runway into the third quarter of 2028.
Revenue recognized was $13.2 million in Q3 2026, versus $7.6 million in Q3 2025.
Research and development expenses were $53.8 million and general and administrative expenses were $25.4 million in Q3 2026.
Net loss was $61.9 million, or $0.30 per share, versus a net loss of $53.9 million, or $0.32 per share, a year earlier.
Cash, cash equivalents, and marketable securities were $431.0 million at September 30, 2026, excluding a $12 million GSK milestone due in Q4 2026.
Wave Life Sciences reported second-quarter 2026 results with revenue of $2.3 million, down from $8.7 million a year earlier, and a net loss of $69.4 million, up from $50.5 million. The company said cash, cash equivalents, and marketable securities were $490.6 million at June 30, 2026, with cash runway expected into the third quarter of 2028.
Net loss per share was $0.34 in Q2 2026 versus $0.31 in Q2 2025.
Research and development expenses rose to $51.3 million from $43.5 million; general and administrative expenses rose to $24.8 million from $18.0 million.
Cash, cash equivalents, and marketable securities were $490.6 million at June 30, 2026, versus $602.1 million at December 31, 2025.
An FDA meeting on a potential accelerated approval pathway for WVE-006 is scheduled for the end of summer 2026.
Wave Life Sciences released updated clinical data from the ongoing Phase 1b/2a RestorAATion-2 trial of WVE-006, an investigational RNA editing therapy for alpha-1 antitrypsin deficiency, and said it expects FDA feedback on a potential accelerated approval pathway in mid-2026. The data are early-stage, from small cohorts of eight patients each, and the company has not reported a trial outcome or regulatory decision, so the update's significance for shareholders depends on future regulatory and clinical results.
Single-dose 200 mg, 400 mg and 600 mg cohorts reached Z-AAT reductions of 47.3%, 49.7% and 59.1% from baseline, per the filing.
Multidose 200 mg biweekly cohort reached 70.5% Z-AAT reduction and total AAT of 11.9 µM; 400 mg monthly cohort reached 67.7% reduction and 13.6 µM.
Company expects FDA feedback on a potential accelerated approval pathway mid-2026 and data from the 600 mg multidose cohort in the second half of 2026.
All adverse events were mild to moderate, with no serious adverse events, according to the company.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Wave Life Sciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →